Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

UK Health Body Approves Novartis's Tasigna For CML

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2012 | 01:16am CET

The U.K.'s health-cost regulator has decided to back an expensive cancer drug from Novartis AG (NVS) for treating chronic myeloid leukemia--but not one from U.S.-based Bristol-Myers Squibb Co. (BMY)--after the Swiss drug maker offered to cut the drug's price.

The independent National Institute for Clinical Excellence, known by its acronym NICE, said Wednesday it approved Novartis's Tasigna and the company's older drug, whose brand name is Glivec, for use in treating CML on the publicly funded National Health Service. The generic names for Tasigna and Glivec are nilotinib and imatinib, respectively.

However, NICE said it wasn't approving Bristol-Myers Squibb's Sprycel, also known as dasatinib.

CML is a cancer of blood-forming cells in the bone marrow that usually develops slowly, which is why it is described as a chronic form of the disease.

NICE director Carole Longson said: "The recommendations reaffirm the use of imatinib as an effective treatment for the majority of patients and a cost-effective use of NHS resources, and we are also very pleased to be able to add a further treatment option for these patients by recommending nilotinib.

"Although no trials directly comparing dasatinib and nilotinib were available, the committee concluded from indirect comparisons that dasatinib and nilotinib could be considered equally as effective in treating CML.

"However, the manufacturer of nilotinib has already agreed with the Department of Health to provide the drug to the NHS at a discounted price. This reduction in cost enabled the independent committee to approve nilotinib for use on the NHS."

Dasatinib and nilotinib both cost over GBP30,000 per patient a year and the standard dose of imatinib costs GBP20,000.

NICE didn't disclose the price discount offered by Novartis for nilotinib.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS AG
05:47p SCOTT MEACHAM : Selexys exit validates Oklahoma as place to start biotech firms
01:01a NOVARTIS : presents results from first global registration trial of CTL019 in pe..
12/03 NOVARTIS : SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequenc..
12/02 Pieris Pharmaceuticals Appoints Claude Knopf as Chief Business Officer
12/01 NOVARTIS : Patent Issued for Minimal Pulsation Ophthalmic Probe (USPTO 9498378)
11/30 NOVARTIS : Access shares one-year learnings and announces memorandum of understa..
11/30 NOVARTIS : Alcon Lensx Assigned Patent
11/29 NOVARTIS : Payments to Healthcare Professionals
11/29 NOVARTIS : Access shares one-year learnings and announces memorandum of understa..
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
More news
Sector news : Pharmaceuticals - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12:19p Novartis' CAR T candidate CTL019 demonstrates 82% complete response rate in m..
12/03 Barron's searches for value in its top stock picks for 2017
12/02 Bond Beatdown Creates Major Dislocations With 4 Stocks Posing Great Opportuni..
12/01 Significant Upside Potential For Ophthotech Before Phase 3 Fovista Readout
12/01 Triple Meeting - Bluebird Upstages Its Ash Rivals
Advertisement
Financials ($)
Sales 2016 48 805 M
EBIT 2016 11 856 M
Net income 2016 7 810 M
Debt 2016 15 084 M
Yield 2016 4,16%
P/E ratio 2016 19,70
P/E ratio 2017 18,53
EV / Sales 2016 3,97x
EV / Sales 2017 3,89x
Capitalization 178 737 M
More Financials
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 83,3 $
Spread / Average Target 22%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-19.07%178 737
JOHNSON & JOHNSON9.00%304 591
PFIZER INC.-2.01%191 942
ROCHE HOLDING LTD.-19.61%188 878
MERCK & CO., INC.15.85%168 544
SANOFI-4.20%103 510
More Results